Anita A. Mathias, Ph.D.
Affiliations: | 2004 | University of Washington, Seattle, Seattle, WA |
Area:
Pharmacy, Obstetrics and GynecologyGoogle:
"Anita Mathias"Mean distance: 23748
Parents
Sign in to add mentor| Jashvant D. Unadkat | grad student | 2004 | University of Washington | |
| (Disposition of anti -HIV protease inhibitors in pregnancy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kirby BJ, Lutz JD, Yue MS, et al. (2020) OATP Inhibition Dramatically Increases Plasma Exposure, but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure, of Firsocostat. Clinical Pharmacology and Therapeutics |
| Kumar V, Yin M, Ishida K, et al. (2020) Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Reyes M, Lutz JD, Lau AH, et al. (2020) Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects. Antiviral Therapy |
| Humeniuk R, Mathias A, Cao H, et al. (2020) Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects. Clinical and Translational Science |
| Meng A, Anderson K, Nelson C, et al. (2020) Sat0149 Exposure-Response Relationships For Efficacy And Safety Of Filgotinib And Its Metabolite Gs-829845 In Subjects With Rheumatoid Arthritis Based On Phase 2 And Phase 3 Studies Annals of the Rheumatic Diseases. 79: 1013-1014 |
| Kumar V, Ishida K, Salphati L, et al. (2020) P129 - In-vivo transporter-mediated hepatic clearance of rosuvastatin in humans could be better predicted using transporter-expressing cells than hepatocytes Drug Metabolism and Pharmacokinetics. 35 |
| Anderson K, Xin Y, Zheng H, et al. (2019) Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects. Clinical Pharmacology in Drug Development |
| Kumar V, Salphati L, Hop CECA, et al. (2019) A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes vs. Human Liver Tissue Using Quantitative Targeted Proteomics and Cell-Surface Biotinylation. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Begley R, Meng A, Massetto B, et al. (2019) IDDF2019-ABS-0135 Pharmacokinetics of once-daily sofosbuvir or ledipasvir/sofosbuvir in HCV-infected pediatrics aged 3 to Gut. 68 |
| Anderson K, Zheng H, Medzihradsky O, et al. (2019) Thu0117 Pharmacokinetics And Short-Term Safety Of Filgotinib, A Selective Janus Kinase 1 Inhibitor, In Subjects With Moderate Hepatic Impairment Annals of the Rheumatic Diseases. 78: 331-331 |